MN-166 may be an effective new approach to treating MS with the added advantage of oral dosing. Rapid completion of enrollment in this relatively large trial demonstrates our commitment to advancing our clinical programs efficiently though the Phase II proof-of-concept stage and beyond.
Yuichi Iwaki
trial commitment completion stage
You must log in to post a comment.
There are no comments yet.